All In Biotech

NDA 210942 · Scilex Pharms

Gloperba

Colchicine · Oral · Alkaloid

Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jan 30, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

313

94 Phase 3, 51 recruiting

FAERS reports

26,563

21,606 serious, 3,267 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 1, 2024.

GLOPERBA ® (colchicine) Oral Solution is indicated for prophylaxis of gout flares in adults. GLOPERBA is indicated for prophylaxis of gout flares in adults ( 1 ). Limitations of use: The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied. GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes ( 1 ). Limitations of use: The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied. GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.

Mechanism: Colchicine's effectiveness as a prophylactic treatment for gout has been postulated to be due to its ability to block neutrophil mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation and migration of neutrophils to sites of inflammation. Colchicine also interferes with the inflammasome complex found in neutrophils and monocytes that mediates interleukin-1β (IL-1β) activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • GLOPERBA · COLCHICINE 0.6MG/5ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Colchicine" as an intervention, any sponsor and status, largest first.

All 313 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,429
  • off label use2,256
  • drug ineffective2,052
  • nausea1,809
  • fatigue1,643
  • dyspnoea1,371
  • arthralgia1,356
  • acute kidney injury1,318
  • headache1,279
  • vomiting1,240
  • toxicity to various agents1,230
  • pain1,135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004223
2005284
2006236
2007232
2008253
2009419
2010536
2011816
2012695
2013564
2014625
2015970
20161,281
20171,272
20181,594
20192,117
20202,139
20211,802
20221,952
20232,096
20242,220
20252,493
20261,743

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gloperba (Colchicine)

2024 spending

$33K

Beneficiaries

29

52 claims

Per beneficiary

$1,130

$3.87 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$32,757

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 768 on PubMed

Sponsor: Scilex Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.